Targeted Therapies in Patients with Pulmonary Arterial Hypertension Due to Congenital Heart Disease
Authors:
- 1 July 2022
- journal article
- review article
- Published by Bentham Science Publishers Ltd. in Current Vascular Pharmacology
- Vol. 20 (4) , 341-360
Abstract
Pulmonary arterial hypertension [PAH] is a devastating cardiovascular disease leading to right heart failure and death if untreated. Medical therapies for PAH have evolved substantially over the last decades and are associated with improvements in functional class, quality of life, and survival. PAH-targeted therapies now consist of multiple inhaled, oral, subcutaneous, and intravenous therapies targeting the phosphodiesterase, guanylate cyclase, endothelin and prostacyclin pathways. Patients with congenital heart disease [CHD] are at high risk of developing PAH and growing evidence exists that PAH-targeted therapy can be beneficial in PAH-CHD. However, the PAH-CHD patient population is challenging to treat due to the heterogeneity and complexity of their cardiac lesions and associated comorbidities. Furthermore, most high-quality randomized placebo-controlled trials investigating the effects of PAH-targeted therapies only included a minority of PAH-CHD patients. Few randomized, controlled trials have investigated the effects of PAH-targeted therapy in pre-specified PAH-CHD populations. Consequently, the results of these clinical trials cannot be extrapolated broadly to the PAH-CHD population. This review summarizes the data from high-quality clinical PAH treatment trials with a specific focus on the PAH-CAD?? population.Keywords
This publication has 73 references indexed in Scilit:
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- Therapy for pulmonary arterial hypertension due to congenital heart disease and Down's syndromeInternational Journal of Cardiology, 2013
- Oral sildenafil treatment for Eisenmenger syndrome: a prospective, open-label, multicentre studyHeart, 2011
- Diagnosis of Pulmonary Hypertension in the Congenital Heart Disease Adult PopulationJACC, 2011
- Improved Survival Among Patients With Eisenmenger Syndrome Receiving Advanced Therapy for Pulmonary Arterial HypertensionCirculation, 2010
- Effect of Bosentan on Exercise Capacity and Quality of Life in Adults With Pulmonary Arterial Hypertension Associated With Congenital Heart Disease With and Without Down's SyndromeThe American Journal of Cardiology, 2009
- Role of oral sildenafil in severe pulmonary arterial hypertension: Clinical efficacy and dose response relationshipInternational Journal of Cardiology, 2006
- Long-term oral bosentan treatment in patients with pulmonary arterial hypertension related to congenital heart disease: a 2-year studyHeart, 2006
- A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertensionAmerican Heart Journal, 2006
- Vascular structure in lung tissue obtained at biopsy correlated with pulmonary hemodynamic findings after repair of congenital heart defects.Circulation, 1984